RIMS binding protein 3BGenealiases: RIM-BP3.2 · RIM-BP3.B · RIMBP3.2
Q-omics provides the consensus-scored RIMBP3B profile across patient tissues and cancer cell-line models. RIMBP3B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RIMBP3B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RIMBP3B RNA expression shows 8,173 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, KIRC, and THYM as cancer lineages where RIMBP3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIMBP3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIMBP3B survival associations across molecular data types. RIMBP3B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIMBP3B RNA expression–survival associations across cancer types. High RIMBP3B expression shows unfavorable associations in KICH, LUSC, BRCA and ACC, but favorable associations in THCA and MESO. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify THCA as the clearest survival context for RIMBP3B RNA expression.
This table summarizes RIMBP3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RIMBP3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIMBP3B shows higher tumor expression in KIRC, BRCA, BLCA, STAD, THCA and LIHC. The KIRC box plot shows higher RIMBP3B RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p < 0.001).
This table shows molecular features associated with RIMBP3B in patient tissues and cancer cell lines. In patient samples, RIMBP3B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIMBP3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
